Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • Accelerated Patent Examination,  China,  China Patent Office,  CNIPA,  Hong Kong,  Inventions,  Prioritized Examination

    BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

    January 4, 2023

    New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To be eligible, the patent application must be: To request a prioritized examination, the applicant will need to submit a request form along with other required documents to the CNIPA at one of the representative offices in Guangdong or Shenzhen, by mail or in person. Of particular note, applicants must submit information about the existing technology…

    Read More
    eagleip No Comments

    Related Posts

    Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

    January 10, 2023
  • China,  Court Cases,  Courts,  Drafting,  Inventions,  Patent Law,  Patent Re-examination Board,  Quality,  Supreme People's Court

    Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

    December 13, 2022

    There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an inventor and literally describe the features of an invention. Worst yet, some inventors try to draft their own application, making the similar mistake of describing an invention too specifically and narrowly, leaving plenty of “design-around” space. Even though a patent may grant, the protection scope for that invention is weak, at best, and may even…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • China,  Examination Guide,  Inventions,  Patent Law,  Proposed Changes,  Updates and Changes

    China Announcing More Proposed Amendments to the Examination Guidelines in 2022

    November 17, 2022

    It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published[1], this time consolidating the previous sets of proposed changes from 2020 to 2021 to the Examination Guidelines. As this version looks closer to a finalized version, we are cautiously optimistic that an official set of guidelines may soon be released. As such, we think it’s worth looking a bit more closely into this current draft version. Below are a…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
 Older Posts
Newer Posts 

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard

Categories

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard
  • May 22, 2026 Breaking: China Released Drug Trial Data Protection Implementation Measures
  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
© 2026 Eagle IP Limited
Savona Theme by Optima Themes